After brokering the sale of ATL Ultrasound to Royal Philips Electronics of the Netherlands (SCAN 8/5/98), chairman and CEO Dennis Fill has moved on to a new venture. Fill last month was named president and CEO of Cytran, a new
After brokering the sale of ATL Ultrasound to Royal Philips Electronics of the Netherlands (SCAN 8/5/98), chairman and CEO Dennis Fill has moved on to a new venture. Fill last month was named president and CEO of Cytran, a new pharmaceutical company based in Kirkland, WA. Effective March 1, he replaced Cytrans former CEO, Philip Syrdal. Fill served as CEO of Bothell, WA-based ATL from 1987 through December 1998. Cytran was founded in 1991 and develops peptide compounds for the treatment of cancer and modulation of the immune system.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.